middle.news
FDA Hits Pause on Argenica’s US Stroke Trial IND Application
9:00am on Tuesday 10th of June, 2025 AEST
•
Biotechnology
Read Story
FDA Hits Pause on Argenica’s US Stroke Trial IND Application
9:00am on Tuesday 10th of June, 2025 AEST
Key Points
FDA places clinical hold on Argenica’s US IND application for Acute Ischaemic Stroke trial
Non-clinical data package deemed insufficient by FDA
Company expects detailed FDA feedback within 30 days
Australian Phase 2 trial progressing as planned with data expected Q3 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argenica Therapeutics (ASX:AGN)
OPEN ARTICLE